Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heleen Scheerens

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in Immunology|August 27, 2014
Targeting IgE production in mice and humansLawren C Wu, Heleen Scheerens
Advances in Pharmacology (San Diego, Calif.)|February 26, 2013
Redefining approaches to asthma: developing targeted biologic therapiesJoseph R Arron, Heleen Scheerens, John G Matthews
Annals of the American Thoracic Society|December 10, 2013
Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthmaJoseph R Arron, David F Choy, Heleen Scheerens, et al.
Bioanalysis|February 6, 2016
Bioanalytical challenges and improved detection of circulating levels of IL-13Fang Cai, Hans Hornauer, Kun Peng, et al.
Journal of Periodontal Research|April 23, 2004
Accelerated alveolar bone loss in mice lacking interleukin-10: late onsetAbdulaziz Al-Rasheed, Heleen Scheerens, Apurva K Srivastava, et al.
Arthritis Research & Therapy|October 28, 2011
MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessmentsHeleen Scheerens, Zheng Su, Bryan Irving, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2013
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroidsMichael Noonan, Phillip Korenblat, Sofia Mosesova, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 20, 2022
Integrated systems modeling of severe asthma: Exploration of IL-33/ST2 antagonismKapil Gadkar, Justin Feigelman, Siddharth Sukumaran, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|November 22, 2002
Regulation of postischemic liver injury following different durations of ischemiaIan N Hines, Jason M Hoffman, Heleen Scheerens, et al.
The Journal of Clinical Investigation|May 4, 2006
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6David Yen, Jeanne Cheung, Heleen Scheerens, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in Immunology|August 27, 2014
Targeting IgE production in mice and humansLawren C Wu, Heleen Scheerens
Advances in Pharmacology (San Diego, Calif.)|February 26, 2013
Redefining approaches to asthma: developing targeted biologic therapiesJoseph R Arron, Heleen Scheerens, John G Matthews
Annals of the American Thoracic Society|December 10, 2013
Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthmaJoseph R Arron, David F Choy, Heleen Scheerens, et al.
Bioanalysis|February 6, 2016
Bioanalytical challenges and improved detection of circulating levels of IL-13Fang Cai, Hans Hornauer, Kun Peng, et al.
Journal of Periodontal Research|April 23, 2004
Accelerated alveolar bone loss in mice lacking interleukin-10: late onsetAbdulaziz Al-Rasheed, Heleen Scheerens, Apurva K Srivastava, et al.
Arthritis Research & Therapy|October 28, 2011
MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessmentsHeleen Scheerens, Zheng Su, Bryan Irving, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2013
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroidsMichael Noonan, Phillip Korenblat, Sofia Mosesova, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 20, 2022
Integrated systems modeling of severe asthma: Exploration of IL-33/ST2 antagonismKapil Gadkar, Justin Feigelman, Siddharth Sukumaran, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|November 22, 2002
Regulation of postischemic liver injury following different durations of ischemiaIan N Hines, Jason M Hoffman, Heleen Scheerens, et al.
The Journal of Clinical Investigation|May 4, 2006
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6David Yen, Jeanne Cheung, Heleen Scheerens, et al.
Pageof 2